Paulson & Co. Votes in Support of Mylan's Proposed Merger with Perrigo

NEW YORK, Aug. 14, 2015 /PRNewswire/ -- On behalf of funds that it manages, Paulson & Co. today voted all of its 21.9 million Mylan MYL shares in support of the proposed merger with Perrigo PRGO. 

John Paulson, President of Paulson & Co., said "The combination of Mylan's unparalleled generic capabilities with Perrigo's attractive OTC platform would create a global pharmaceutical powerhouse. The combined company will benefit from the growth in generics and OTC plus the migration of generics to OTC for many years to come. Mylan management has a successful track record of integrating acquisitions. The transaction is expected to be accretive based on cost synergies alone and likely meaningfully accretive when revenue synergies are taken into account."

Paulson & Co., founded in 1994 is an investment management firm specializing in event-driven strategies. Paulson has approximately US$20 billion in assets under management and has offices in New York, London and Hong Kong.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/paulson--co-votes-in-support-of-mylans-proposed-merger-with-perrigo-300128801.html

SOURCE Paulson & Co. Inc.